This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alkermes' Vivitrol Wins New Approval

WALTHAM, Mass. ( TheStreet) -- Alkermes (ALKS - Get Report) has received U.S. regulatory approval to market its addiction drug Vivitrol as a once-monthly injection to treat people addicted to opioid painkillers, the company announced Tuesday night.

This is the second and more significant U.S. approval for Vivitrol, which was originally cleared in 2006 to treat alcohol addiction. Vivitrol has not performed well commercially to date -- just $20 million in sales last fiscal year -- because doctors are not accustomed to treating alcoholics with drugs.

Alkermes is expected to do much better with Vivitrol now that the U.S. Food and Drug Administration approved an expanded label for opioid addiction, including a claim that Vivitrol can prevent relapse.

Addiction specialists routinely use other narcotic drugs like methadone and Suboxone to treat people hooked on heroin and opioid painkillers. Suboxone, for instance, generates almost $1 billion in annual sales worldwide.

Vivitrol is the first non-narcotic, non-addictive treatment option for opioid addiction. The drug is given via a monthly injection and works by blocking the receptors in the brain, which when activated by opioids, causes the euphoria or high that addicts crave.

By comparison, methadone and Suboxone are both narcotics and addictive, giving addicts a partial or controlled high but which keeps them from seeking drugs on the street.

"Addiction is a serious problem in this country, and can have devastating effects on individuals who are drug-dependent, and on their family members and society," said Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research. "This drug approval represents a significant advancement in addiction treatment."

Tuesday's approval of Vivitrol for opioid addiction was widely expected by investors after an FDA advisory panel voted in September to recommend the drug's clearance. Alkermes shares are up about 10% since that Sept. 16 panel, closing Tuesday at $15.68.

While the Street expected Vivitrol's new approval, sales forecasts are still relatively modest mainly due to the drug's prior poor performance. J.P. Morgan analyst Cory Kasimov, for example, models $51 million in Vivitrol sales in fiscal year 2013.

In a note to clients Wednesday, however, Kasimov lays out the case for why Vivitrol's new approval could have meaningful upside for Alkermes' bottom line and valuation:

"If we were to hypothetically bump that '13 number to $200M (still only one-fifth of what Suboxone is currently generating), our [Alkermes] EPS estimate would jump to $1.48 from $0.65. We think very few investors currently appreciate this degree of leverage," he writes. Kasimov rates Alkermes at overweight with a $19 price target.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ALKS $39.47 -2.20%
LLY $76.15 -0.78%
AAPL $94.50 0.92%
FB $117.69 -0.74%
GOOG $693.13 -0.73%


Chart of I:DJI
DOW 17,699.37 -191.79 -1.07%
S&P 500 2,060.40 -21.03 -1.01%
NASDAQ 4,763.4950 -54.0990 -1.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs